GYREGyre Therapeutics, Inc.
$6.76-7.0% 1Y
$6.76
$5.5652 weeks$8.87
Is the price fair?
What GYRE's price assumes
Gyre Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 6.64× revenue.
6.64
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 7.67
Price / book · as of 2026-Q1
- EV / sales
- 6.33
EV / sales
Details›
- Price / bookas of 2026-Q1
- 7.67
- EV / EBIToperating margin −14%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 6.33
- Market capitalisation
- $656M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.